Pennington Joseph Daniel, Eilber Fritz C, Eilber Frederick R, Singh Arun S, Reed Jarred P, Chmielowski Bartosz, Eckardt Jeffrey J, Bukata Susan V, Bernthal Nicholas M, Federman Noah, Nelson Scott D, Dry Sarah M, Wang Pin-Chieh, Luu Michael, Selch Michael T, Steinberg Michael L, Kalbasi Anusha, Kamrava Mitchell
Departments of Radiation Oncology.
Surgery.
Am J Clin Oncol. 2018 Dec;41(12):1154-1161. doi: 10.1097/COC.0000000000000443.
The objective of this study was to analyze outcomes for patients with soft tissue sarcoma of the extremities using neoadjuvant ifosfamide-based chemotherapy and hypofractionated reduced dose radiotherapy, followed by limb-sparing surgery.
An Institutional Review Board (IRB)-approved retrospective review of patients treated at a single institution between 1990 and 2013 was performed. In total, 116 patients were identified who received neoadjuvant ifosfamide-based chemotherapy and 28 Gy in 8 fractions of preoperative radiation (equivalent dose in 2 Gray fractions, 31.5 Gy [α/β 10] 36.4 Gy [α/β 3]) followed by limb-sparing surgery. Local recurrence (LR), distant failure (DF), and overall survival (OS) were calculated. Univariate and multivariate analysis for LR, DF, and OS were performed using Cox analysis. Statistical significance was set at a P<0.05.
Median follow-up was 5.9 years (range, 0.3 to 24 y). Actuarial LR at 3/6 years was 11%/17%, DF at 3/6 years was 25%/35%, and OS at 3/6 years was 82%/67%. On multivariate analysis, only a positive surgical margin was significantly correlated with worse local control (P=0.005; hazard ratio [HR], 18.33; 95% confidence interval (CI), 2.41-139.34). Age over 60 years (P=0.03; HR, 2.34; 95% CI, 1.10-4.98) and tumor size over 10 cm compared with tumor size ≤5 cm (P=0.03; HR, 3.32; 95% CI, 1.15-9.61) were associated with worse OS.
Soft tissue extremity sarcoma patients treated using reduced dose hypofractionated preoperative radiotherapy in combination with ifosfamide-based chemotherapy shows acceptable local control and warrants further investigation.
本研究的目的是分析采用基于异环磷酰胺的新辅助化疗和低分割减量放疗,随后进行保肢手术的四肢软组织肉瘤患者的治疗结果。
对1990年至2013年在单一机构接受治疗的患者进行了一项经机构审查委员会(IRB)批准的回顾性研究。总共确定了116例接受基于异环磷酰胺的新辅助化疗和术前8次分割共28 Gy放疗(2 Gy分割等效剂量,α/β = 10时为31.5 Gy,α/β = 3时为36.4 Gy),随后进行保肢手术的患者。计算局部复发(LR)、远处转移(DF)和总生存期(OS)。使用Cox分析对LR、DF和OS进行单因素和多因素分析。统计学显著性设定为P<0.05。
中位随访时间为5.9年(范围0.3至24年)。3/6年的精算LR为11%/17%,3/6年的DF为25%/35%,3/6年的OS为82%/67%。多因素分析显示,只有手术切缘阳性与较差的局部控制显著相关(P = 0.005;风险比[HR],18.33;95%置信区间[CI],2.41 - 139.34)。与肿瘤大小≤5 cm相比,年龄超过60岁(P = 0.03;HR,2.34;95% CI,1.10 - 4.98)和肿瘤大小超过10 cm(P = 0.03;HR,3.32;95% CI,1.15 - 9.61)与较差的OS相关。
采用减量低分割术前放疗联合基于异环磷酰胺的化疗治疗四肢软组织肉瘤患者,显示出可接受的局部控制效果,值得进一步研究。